We are live on ! Find out more
ZBIO

ProShares UltraPro Short NASDAQ Biotechnology
ZBIO

Delisted

ZBIO was delisted on the 27th of March, 2020.

Back to rankings

1 hedge funds and large institutions have $9K invested in ProShares UltraPro Short NASDAQ Biotechnology in 2020 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% less funds holding

Funds holding: 5 → 1 (-4)

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

98% less capital invested

Capital invested by funds: $441K → $9K (-$432K)

Holders
1
Holders Change
-4
Holders Change %
-80%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Simplex Trading
Simplex Trading
Illinois
+$10.1K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$186K
2
Citadel Advisors
Citadel Advisors
Florida
-$147K
3
TRCT
Tower Research Capital (TRC)
New York
-$79K
4
Morgan Stanley
Morgan Stanley
New York
-$17K
5
UBS Group
UBS Group
Switzerland
-$12K
Name Holding Trade Value Shares
Change 		Change in
Stake
Simplex Trading
1
Simplex Trading
Illinois
$9K +$10.1K +1,026 New
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
– -$186K -20,322 Closed
Citadel Advisors
3
Citadel Advisors
Florida
– -$147K -16,056 Closed
TRCT
4
Tower Research Capital (TRC)
New York
– -$79K -8,651 Closed
Morgan Stanley
5
Morgan Stanley
New York
– -$17K -1,905 Closed
UBS Group
6
UBS Group
Switzerland
– -$12K -1,346 Closed

ZBIO Hedge Fund Activity: Q1 2020 in Review

1 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) for Q1 2020, worth a combined $9K — down 98% from $441K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of ZBIO and 1 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was Simplex Trading, opening a new position worth an estimated $10.1K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $186K sold.

  • 1 institutional investor held ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) as of Q1 2020, down from 5 in Q4 2019.
  • Funds reported $9K of ProShares UltraPro Short NASDAQ Biotechnology stock for Q1 2020, down 98% quarter-over-quarter.
  • 1 fund opened new ProShares UltraPro Short NASDAQ Biotechnology positions in Q1 2020 and 5 closed out, a net change of -4 holders.
  • The largest ProShares UltraPro Short NASDAQ Biotechnology buyer in Q1 2020 was Simplex Trading, an estimated $10.1K added.
  • The largest ProShares UltraPro Short NASDAQ Biotechnology seller in Q1 2020 was Susquehanna International Group, an estimated $186K sold.

Based on aggregated 13F filings for Q1 2020.